LVP Pharma invests in Rameda’s operations in Egypt for EGP 1.14 billion

Lead party: LimeVest Partners (lead investor/buyer)Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed). Target: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (public company) · Sector: Healthcare, Pharmaceuticals, Medical Supplies · Countries of operation: Egypt Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity…


Lead party: LimeVest Partners (lead investor/buyer)

Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).

Target: Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. (public company) · Sector: Healthcare, Pharmaceuticals, Medical Supplies · Countries of operation: Egypt

Transaction type: Investment · Asset class: Private Equity · Strategy: Growth Equity · Instrument: Ordinary Shares (Equity) · Round: Growth Capital · Deal amount: US$21.7m · Equity stake: 0.1135% · Implied EV: US$190.8m · Fund: LimeVest Partners (LVP) Pharma

Lead investor/buyer: LimeVest Partners · Investors/buyers: LimeVest Partners

Legal advisers: not identified in the source record.

Source: announced 4 June 2026. Original announcement: dailynewsegypt.com.